Lantern Pharma Inc. has announced its financial results for the first quarter of 2025. The company reported cash, cash equivalents, and marketable securities of approximately $19.7 million as of March 31, 2025, a decrease from approximately $24.0 million at December 31, 2024. Research and development expenses were approximately $3.3 million for the quarter ended March 31, 2025, compared to approximately $4.3 million for the same period in 2024. Significant operational updates include the anticipated completion of LP-184 Phase 1a clinical trial enrollment with 62-65 patients across a range of solid tumors by the end of June 2025. Additionally, a data readout from the HARMONIC™ Trial evaluating LP-300 in never-smokers with non-small cell lung cancer is expected in Q3 2025, including initial data from the Asian expansion cohort. Lantern Pharma has also strengthened its AI intellectual property portfolio with the PCT publication of a proprietary blood-brain barrier penetration prediction patent application. The company maintains a disciplined capital management approach, providing an operating runway through at least May 15, 2026.